Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...
Effective drug discovery and development hinge on high-quality data. Implementing FAIR principles enhances data usability and ...
High antibody titers of anti–citrullinated peptide antibodies, rheumatoid factor, and certain baseline factors predict RA ...
With AI use on the rise, clinical development is also not far behind in using AI technology. AI is actively changing how ...
Clinical Trials Arena on MSN7d
How to integrate patients into clinical research with cohesive strategiesAn upcoming meeting will explore the patient’s role in clinical research and different CRO-sponsor relationship models amid a ...
For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...
Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ...
Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback